Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIX HER2
2023-508411-23-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Nov 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pertuzumab, trastuzumab emtansine and docetaxel in breast cancer, sponsored by Karolinska University Hospital. Primary endpoint: Pathological objective response to primary medical treatment. Planned start Nov 2014; status: authorised.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-508411-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508411-23-00.